Coherus Oncology, Inc. (CHRS): auditor change — Coherus Oncology dismisses EY as auditor, appoints PwC effective June 12, 2026

Coherus Oncology, Inc.

Dismissed Ernst & Young as auditor effective June 12, 2026; no adverse opinions or disagreements in prior periods.
Audit committee selected PricewaterhouseCoopers as new auditor for FY 2026, subject to standard client acceptance.
A material weakness in internal control over inventory reconciliations reported for FY 2024 was remediated by FY 2025.

item 4.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Auditor Changes SEC 8-K Item 4.01/4.02 confidence 0.9

Coherus Oncology, Inc. dismissed Ernst & Young LLP as its auditor.

Action: dismissal
Auditor: Ernst & Young LLP
Successor: PricewaterhouseCoopers LLP

Exact text from the filing

On June 12, 2026, the Audit Committee (the “Audit Committee”) of the Board of Directors of Coherus Oncology, Inc. (the “Company”) dismissed Ernst & Young LLP (“EY”) as the Company’s independent registered public accounting firm, with dismissal effective as of such date.

View on SEC.gov

Auditor Changes SEC 8-K Item 4.01/4.02 confidence 0.9

Coherus Oncology, Inc. engaged PricewaterhouseCoopers LLP as its auditor.

Action: engagement
Auditor: PricewaterhouseCoopers LLP

Exact text from the filing

On June 12, 2026, the Audit Committee of the Board of Directors of the Company selected PricewaterhouseCoopers LLP (“PwC”) to be appointed to serve as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026, subject to standard client acceptance procedures.

View on SEC.gov

56 auditor changes filed in the last 30 days. Browse all auditor changes →

Coherus Oncology, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-26-074090

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.